Mwanzo9VC • ETR
ATAI Life Sciences NV
€ 2.00
12 Jun, 09:04:23 GMT +2 · EUR · ETR · Kanusho
HisaHisa zinazouzwa DE
Bei iliyotangulia
€ 2.00
Bei za mwaka
€ 0.93 - € 2.50
Thamani ya kampuni katika soko
447.68M USD
Wastani wa hisa zilizouzwa
elfu 5.58
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD)Mac 2025Mabadiliko Tangu Mwaka Uliopita
Mapato
1.56M
Matumizi ya uendeshaji wa biashara
9.99M-8.84%
Mapato halisi
-26.43M1.06%
Kiwango cha faida halisi
elfu -1.70
Mapato kwa kila hisa
-0.1511.76%
EBITDA
-19.05M13.79%
Asilimia ya kodi ya mapato
-0.49%
Jumla ya mali
Jumla ya dhima
(USD)Mac 2025Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
98.20M-7.57%
Jumla ya mali
195.78M-27.25%
Jumla ya dhima
43.51M-5.13%
Jumla ya hisa
152.27M
hisa zilizosalia
200.34M
Uwiano wa bei na thamani
2.62
Faida inayotokana na mali
-27.13%
Faida inayotokana mtaji
-29.67%
Mabadiliko halisi ya pesa taslimu
(USD)Mac 2025Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
-26.43M1.06%
Pesa kutokana na shughuli
-17.84M20.96%
Pesa kutokana na uwekezaji
-11.01M-196.02%
Pesa kutokana na ufadhili
59.60M
Mabadiliko halisi ya pesa taslimu
30.78M375.65%
Mtiririko huru wa pesa
-11.27M38.58%
Kuhusu
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2018
Tovuti
Wafanyakazi
54
Gundua zaidi
Huenda unavutiwa na
Orodha hii imetokana na maudhui uliyotafuta hivi majuzi, hisa unazofuatilia na shughuli zingine. Pata maelezo zaidi

Data na maelezo yote hutolewa “kama yalivyo” kwa madhumuni ya taarifa binafsi tu, wala hayanuii kuwa ushauri wa kifedha na hayana madhumuni ya kufanya biashara au uwekezaji, kodi, kisheria, uhasibu au ushauri mwingine. Google si mshauri wa uwekezaji wala mshauri wa kifedha na haitoi maoni au mapendekezo yanayohusiana na kampuni zozote zilizojumuishwa kwenye orodha hii au hisa zozote zilizotolewa na kampuni hizo. Tafadhali wasiliana na dalali wako au mwakilishi wa kifedha ili uthibitishe bei kabla ya kufanya biashara yoyote. Pata maelezo zaidi
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu